Table 1 ScFv xenoantibodies constructed to study the role of mutations in xenoantibody/gal carbohydrate interaction
ScFv Antibody Clone | Location of Mutations in Amino Acids | Source of cDNA |
|---|---|---|
122B IGHV3-11 patient d10 germline clone | 58, 67 | IgM human xenoantibody clone isolated at day 10 |
33 (IGHV3-11 with mutations) | 28,35,37,50,52a,55,56,57 73, 74, 76, 77, 78, 94 | IgG human xenoantibody clone isolated at day 21 |
193 (IGHV3-11 with mutations) | 23,24,55,67,73,74,77,93 | IgG human xenoantibody clone isolated at day 21 |
511 (IGHV3-11 site-directed mutation) | 31,47 | Site-directed mutagenesis of germline IGHV3-11 clone in germline configuration |
528 (IGHV3-11 site-directed mutation) | 31 | Site-directed mutagenesis to modify amino acid #31 in the IGHV3-11 clone expressed in patients at day 10. |
50D (IGHV3-11 site-directed mutation) | 50 | Site-directed mutagenesis to modify amino acid #50 in the IGHV3-11 clone expressed in patients at day 10. |
54D (IGHV3-11 site-directed mutation) | 54 | Site-directed mutagenesis to modify amino acid #54 in the IGHV3-11 clone expressed in patients at day 10. |